Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2022 | 1566.67% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 51.52% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 51.52% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 89.39% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 51.52% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 278.79% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 506.06% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 430.3% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/22/2022 | 1566.67% | 查丹資本 | $2 → 22 美元 | 維護 | 買 |
| 08/16/2022 | 51.52% | 查丹資本 | 2.5 美元 → 2 美元 | 維護 | 買 |
| 02/09/2022 | 51.52% | BTIG | 5 美元 → 2 美元 | 維護 | 買 |
| 2021 年 12 月 20 日 | 89.39% | 查丹資本 | 8 美元 → 2.5 美元 | 維護 | 買 |
| 2021 年 12 月 16 日 | 51.52% | HC Wainwright & Co. | → 2 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 9 月 15 日 | 278.79% | BTIG | → 5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 4 月 9 日 | 506.06% | 查丹資本 | 7 美元 → 8 美元 | 維護 | 買 |
| 2020 年 5 月 6 日 | 430.3% | 查丹資本 | → 7 美元 | 啓動覆蓋範圍開啓 | → 購買 |
Sonnet BioTherapeutics Questions & Answers
十四行詩生物療法問題與解答
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by Chardan Capital on September 22, 2022. The analyst firm set a price target for $22.00 expecting SONN to rise to within 12 months (a possible 1566.67% upside). 5 analyst firms have reported ratings in the last year.
查丹資本於2022年9月22日公佈了Sonnet BioTherapeutics（納斯達克股票代碼：SONN）的最新目標股價。該分析公司將目標股價定爲22.00美元，預計SONN將在12個月內升至12個月內（可能上漲1566.67％）。去年有5家分析公司公佈了評級。
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by Chardan Capital, and Sonnet BioTherapeutics maintained their buy rating.
Sonnet BioTherapeutics（納斯達克股票代碼：SONN）的最新分析師評級由Chardan Capital提供，Sonnet BioTherapeutics維持買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on September 22, 2022 so you should expect the next rating to be made available sometime around September 22, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Sonnet BioTherapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Sonnet BioTherapeutics的最新評級是在2022年9月22日發佈的，因此您應該預計下一個評級將在2023年9月22日左右公佈。
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a maintained with a price target of $2.00 to $22.00. The current price Sonnet BioTherapeutics (SONN) is trading at is $1.32, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但Sonnet BioTherapeutics（SONN）的最新評級維持不變，目標股價爲2.00美元至22.00美元。Sonnet BioTherapeutics（SONN）目前的交易價格爲1.32美元，超出了分析師的預期區間。